We would love to hear your thoughts about our site and services, please take our survey here.
I do indeed know of their part ownership, as we should all do !
However it does not stop them researching Affimer.
We will still have an old fashioned Friday with size buyers moving it above 70, at Friday close .
More news before conference I suspect .
This is the bullish language we will hear at AACR:
"Critically, this financing provides Avacta with 24 months of cash runway to focus on advancing AVA6000 through the clinic, as well as progressing other assets earlier in the development cycle to hit key commercial milestones."
Worth bearing in mind, with a very busy quarter ahead, any further signs of an IPO of Affyxell, will for the first time put a value on Avacta's + 20% nill cost holding and will look very interesting if done post our Avacata own Therapeutic's IPO.
If you look at the valuation Bicycle Therapeutics is trading on and with a very well known M&A hedge fund increasing their stake in BCYC, our to be appointed US syndicate better get a move on or else some very nice transaction fees will fly past and be missed, because the majors are lining up for the AACR and suddenly " I would not worry about that " will look very real.
To pick up stock at current levels , is a gift rarely seen in the market.
Since Avacta technically still owns Coris Concept, worth noting
: Health authorities in Brazil are rushing out limited supplies of a recently approved vaccine as they struggle to contain an unprecedented surge in dengue fever.
Several of Brazil’s most populous states have declared health emergencies in the past month just ahead of carnival season as rising global temperatures and heavy rains brought outbreaks of the tropical disease spread by the Aedes aegypti mosquito.
Brazil has recorded 512 000 dengue cases so far this year—more than three times the number recorded for the same period last year. “We may see the largest number of dengue cases on record this year,
What if :
No placing, but license deal accepted and DX deal in place?
Cash balance looking very strong in front of AACR and further update. Keep hearing AVA3996 quite something , majors at conference would like hear more!
Interesting observation, if one were to compare recent performance of LLY and Novo vs AZN, the weight loss effect on Novo and LLY have resulted in NVO up 70% and LLY up 115% vs AZN - 7% over the last 12 months. So before AACR perhaps the cancer specialist AZN wants to reverse that trend by more M&A in precision oncology sector and look at Avacta Therapeutics for performance.A license deal looks very sensible! They better get a move on, as this year's AACR will be a mega M&A get together.
Lots of fee's to be made. So we should have a license deal with a major very shortly, which will change the rating of Avacta Therapeutics completely.
With hedge funds like Baker brothers stepping up the buying in stocks like Bicycle Therapeutics, pushing the stock 25% up so far in two days , the area looks very interesting as usual and Avacta will look cheaper than ever. A simple read across, makes Avacta Theraprutics during AACR an incredibly well timed IPO , no wonder the excecutives of the " new Avacta Therapeutics " will be residing State side.Sequia will be defending their holding during a very interesting Q2.